DAINIPPON’s ZONISAMIDE ANTI-EPILEPTIC ENTERS PHASE III CLINICALS
Executive Summary
DAINIPPON's ZONISAMIDE ANTI-EPILEPTIC ENTERS PHASE III CLINICALS in the U.S. for the treatment of incurable epileptic convulsions. Dainippon has contracted out the zonisamide trials and NDA to the Institute for Biological Research and Development (IBRD), a clinical test contractor based in Irvine, Calif. IBRD is owned by Kuraya, a major Japanese wholesaler ("The Pink Sheet" Oct. 29, 1990, T&G-8). IBRD reportedly plans to enroll 300 patients for the U.S. study, which will run for two to three years. Zonisamide currently is marketed in Japan under the brand name Excegran for the treatment of patients with refractory epilepsies. Dainippon originally granted zonisamide licensing rights in the U.S. to Warner-Lambert, who filed for an IND in 1982. The U.S. firm conducted patient trials until 1987 when it decided to discontinue studying the drug. Warner-Lambert returned the licensing rights to Dainippon; the two companies currently are in negotiations about an IND transfer. Dainippon opened its first U.S. office in New York three-and-a-half years ago. Zonisamide is one of three drugs under development by the Japanese company for sale in the U.S. market: interleukin-1 alpha, an anticancer/radioprotectant myelorestorative agent, is in Phase II clinicals, while biosynthetic human IL-8 is in development under a cooperative agreement with the National Cancer Insititute.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth